# Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation

> **NCT00464165** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 789 (actual)

## Conditions studied

- Smoking Cessation

## Interventions

- **DRUG:** rimonabant

## Key facts

- **NCT ID:** NCT00464165
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 789 (ACTUAL)
- **Last updated:** 2010-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00464165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00464165, "Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00464165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*